

Onno J Arntz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/988017/publications.pdf>

Version: 2024-02-01

58
papers

3,090
citations

212478

28
h-index

214428

50
g-index

58
all docs

58
docs citations

58
times ranked

2984
citing authors

#	ARTICLE	IF	CITATIONS
1	Bovine Milk-Derived Extracellular Vesicles Inhibit Catabolic and Inflammatory Processes in Cartilage from Osteoarthritis Patients. <i>Molecular Nutrition and Food Research</i> , 2022, 66, e2100764.	1.5	13
2	Comparing Approaches to Normalize, Quantify, and Characterize Urinary Extracellular Vesicles. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1210-1226.	3.0	53
3	Therapeutic Potential for Regulation of the Nuclear Factor Kappa-B Transcription Factor p65 to Prevent Cellular Senescence and Activation of Pro-Inflammatory in Mesenchymal Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3367.	1.8	20
4	Extracellular vesicles regulate purinergic signaling and epithelial sodium channel expression in renal collecting duct cells. <i>FASEB Journal</i> , 2021, 35, e21506.	0.2	9
5	Flood Control: How Milk-Derived Extracellular Vesicles Can Help to Improve the Intestinal Barrier Function and Break the Gut-Joint Axis in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 703277.	2.2	24
6	Influence of mesenchymal stem cell-derived extracellular vesicles in vitro and their role in ageing. <i>Stem Cell Research and Therapy</i> , 2020, 11, 13.	2.4	32
7	An optimized method for plasma extracellular vesicles isolation to exclude the copresence of biological drugs and plasma proteins which impairs their biological characterization. <i>PLoS ONE</i> , 2020, 15, e0236508.	1.1	8
8	Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity. <i>Frontiers in Immunology</i> , 2018, 9, 2388.	2.2	21
9	Milk-Derived Nanoparticle Fraction Promotes the Formation of Small Osteoclasts But Reduces Bone Resorption. <i>Journal of Cellular Physiology</i> , 2017, 232, 225-233.	2.0	36
10	Disease-inducible interleukin-10 gene therapy suppresses innate cytokine response in the 3d micromass model of the synovial membrane. , 2017, , .		0
11	Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane. <i>Arthritis Research and Therapy</i> , 2016, 18, 186.	1.6	21
12	Milk extracellular vesicles accelerate osteoblastogenesis but impair bone matrix formation. <i>Journal of Nutritional Biochemistry</i> , 2016, 30, 74-84.	1.9	40
13	Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis. <i>Human Gene Therapy</i> , 2016, 27, 244-254.	1.4	54
14	Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 1701-1712.	1.5	205
15	Commercial Cow Milk Contains Physically Stable Extracellular Vesicles Expressing Immunoregulatory TGF- β 2. <i>PLoS ONE</i> , 2015, 10, e0121123.	1.1	163
16	Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2084-2091.	0.5	31
17	In Vivo Molecular Imaging of Cathepsin and Matrix Metalloproteinase Activity Discriminates between Arthritic and Osteoarthritic Processes in Mice. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00001.	0.7	17
18	Serum Samples That Have Been Stored Long-Term (>10 Years) Can Be Used as a Suitable Data Source for Developing Cardiovascular Risk Prediction Models in Large Observational Rheumatoid Arthritis Cohorts. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	7

#	ARTICLE	IF	CITATIONS
19	A5.14â€¦Disease-regulated local interleukin-10 gene therapy diminishes synovitis and articular cartilage damage in experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A68.2-A69.	0.5	1
20	A5.15â€¦The validation of disease-inducible promoter constructs for gene therapy in rheumatoid arthritis and osteoarthritis in human THP-1 cells.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A69.1-A69.	0.5	2
21	Toll-like receptor 4 in bone marrow-derived cells as well as tissue-resident cells participate in aggravating autoimmune destructive arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1407-1415.	0.5	4
22	A6.11â€¦Intra-Articular Overexpression of Interleukin-10 Diminishes Cartilage Proteoglycan Depletion in Streptococcal Cell Wall Arthritis: A Promising Concept for Disease-Regulated Gene Therapy. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A46.1-A46.	0.5	0
23	Intravenous Delivery of HIV-Based Lentiviral Vectors Preferentially Transduces F4/80+ and Ly-6C+ Cells in Spleen, Important Target Cells in Autoimmune Arthritis. <i>PLoS ONE</i> , 2013, 8, e55356.	1.1	9
24	NIR-fluorescence imaging points at a role for matrix-metalloproteinases in causing irreversible cartilage damage during collagen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A61.3-A62.	0.5	0
25	Lack of TLR4 on bone marrow derived cells ameliorates experimental arthritis and decreases cd4⁻IL-17⁺ cells. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A74.2-A75.	0.5	0
26	Enhanced suppressor of cytokine signaling 3 in arthritic cartilage dysregulates human chondrocyte function. <i>Arthritis and Rheumatism</i> , 2012, 64, 3313-3323.	6.7	23
27	Destructive role of myeloid differentiation factor 88 and protective role of TRIF in interleukinâ€“17â€“dependent arthritis in mice. <i>Arthritis and Rheumatism</i> , 2012, 64, 1838-1847.	6.7	20
28	A novel Saa3-promoter reporter distinguishes inflammatory subtypes in experimental arthritis and human synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1311-1319.	0.5	20
29	A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2167-2175.	0.5	20
30	Identifying the TLR4 bearing target cell in experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A42-A42.	0.5	0
31	Toll-like receptor-4 signalling is specifically tak1-independent in synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A16-A17.	0.5	0
32	Toll-like receptor 4 signalling is specifically TGF-beta-activated kinase 1 independent in synovial fibroblasts. <i>Rheumatology</i> , 2011, 50, 1216-1225.	0.9	19
33	The natural soluble form of IL-18 receptor $\hat{1}^2$ exacerbates collagen-induced arthritis via modulation of T-cell immune responses. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 276-283.	0.5	30
34	A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R61.	1.6	21
35	Computational Design and Application of Endogenous Promoters for Transcriptionally Targeted Gene Therapy for Rheumatoid Arthritis. <i>Molecular Therapy</i> , 2009, 17, 1877-1887.	3.7	18
36	Splenic suppressor of cytokine signaling 3 transgene expression affects T cell responses and prevents development of collagenâ€“induced arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3742-3752.	6.7	35

#	ARTICLE	IF	CITATIONS
37	Application of a disease-regulated promoter is a safer mode of local IL-4 gene therapy for arthritis. <i>Gene Therapy</i> , 2007, 14, 1632-1638.	2.3	28
38	791. Unraveling Disease-Inducible Promoters from Gene Expression Profiling for Therapeutic Application in Arthritis. <i>Molecular Therapy</i> , 2006, 13, S306-S307.	3.7	0
39	Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. <i>Osteoarthritis and Cartilage</i> , 2005, 13, 66-73.	0.6	139
40	Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. <i>Arthritis and Rheumatism</i> , 2005, 52, 2202-2211.	6.7	43
41	An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. <i>Gene Therapy</i> , 2004, 11, 581-590.	2.3	55
42	Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: Exacerbation of joint inflammation in STAT-1 gene-knockout mice. <i>Arthritis and Rheumatism</i> , 2004, 50, 2014-2023.	6.7	83
43	Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: A comparative study in gene-deficient mice. <i>Arthritis and Rheumatism</i> , 2003, 48, 1750-1761.	6.7	29
44	Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2949-2958.	6.7	42
45	Adenoviral delivery of IL-18 binding protein C ameliorates Collagen-Induced Arthritis in mice. <i>Gene Therapy</i> , 2003, 10, 1004-1011.	2.3	273
46	Deficiency of NADPH Oxidase Components p47phox and gp91phox Caused Granulomatous Synovitis and Increased Connective Tissue Destruction in Experimental Arthritis Models. <i>American Journal of Pathology</i> , 2003, 163, 1525-1537.	1.9	83
47	Adenoviral Transfer of Murine Oncostatin M Elicits Periosteal Bone Apposition in Knee Joints of Mice, Despite Synovial Inflammation and Up-Regulated Expression of Interleukin-6 and Receptor Activator of Nuclear Factor- κ B Ligand. <i>American Journal of Pathology</i> , 2002, 160, 1733-1743.	1.9	51
48	A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. <i>Gene Therapy</i> , 2001, 8, 1785-1793.	2.3	213
49	Involvement of IL-6, Apart from Its Role in Immunity, in Mediating a Chronic Response during Experimental Arthritis. <i>American Journal of Pathology</i> , 2000, 157, 2081-2091.	1.9	67
50	Animal models of arthritis in NOS2-deficient mice. <i>Osteoarthritis and Cartilage</i> , 1999, 7, 413-415.	0.6	77
51	Reduced cartilage proteoglycan loss during zymosan-induced gonarthritis in NOS2-deficient mice and in anti-interleukin-1-treated wild-type mice with unabated joint inflammation. <i>Arthritis and Rheumatism</i> , 1998, 41, 634-646.	6.7	102
52	DIFFERENT ROLES OF TUMOUR NECROSIS FACTOR α 1 AND INTERLEUKIN 1 IN MURINE STREPTOCOCCAL CELL WALL ARTHRITIS. <i>Cytokine</i> , 1998, 10, 690-702.	1.4	132
53	EFFECT OF INTERLEUKIN 1 AND LEUKAEMIA INHIBITORY FACTOR ON CHONDROCYTE METABOLISM IN ARTICULAR CARTILAGE FROM NORMAL AND INTERLEUKIN-6-DEFICIENT MICE: ROLE OF NITRIC OXIDE AND IL-6 IN THE SUPPRESSION OF PROTEOGLYCAN SYNTHESIS. <i>Cytokine</i> , 1997, 9, 453-462.	1.4	34
54	Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. <i>Arthritis and Rheumatism</i> , 1997, 40, 893-900.	6.7	184

#	ARTICLE	IF	CITATIONS
55	Role of interleukin-1, tumor necrosis factor $\hat{\pm}$, and interleukin-6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis and Rheumatism, 1995, 38, 164-172.	6.7	365
56	In vivo effects of interleukin-1 on articular cartilage. Prolongation of proteoglycan metabolic disturbances in old mice. Arthritis and Rheumatism, 1991, 34, 606-615.	6.7	78
57	In Vivo Evidence for a Key Role of Il-1 in Cartilage Destruction in Experimental Arthritis. , 1991, 32, 159-163.		19
58	Age- and sex-related differences in antigen-induced arthritis in c57bl/10 mice. Arthritis and Rheumatism, 1989, 32, 789-794.	6.7	17